Altered glycosylation of integrin adhesion molecules in colorectal cancer cells and decreased adhesion to the extracellular matrix

B v Lampe, A Stallmach, E O Riecken

Abstract

The integrin mediated interactions between tumour cells and the surrounding extracellular matrix are thought to play crucial parts in the complex process of invasion and metastasis. It has been previously shown that the expression of integrins is differently diminished in a chain-specific manner in human colorectal cancer. To further characterise the integrins still expressed in colorectal carcinomas, immunoblots with monoclonal antibodies against the $\beta_1$ integrin subunit have been performed. In isolated cell membranes of colorectal cancers a second smaller $\beta_1$ chain (105 kD non-reduced) was found as well as the mature $\beta_1$ chain (116 kD non-reduced) present in normal mucosa of the colon. This smaller $\beta_1$ chain comigrates with the diminished glycosylated precursor form of the $\beta_1$ chain. The role of N-glycosylation for the function and expression of integrins in vitro was therefore investigated, with deoxymannojirimycin (DMJ) and deoxynojirimycin (DNJ) as specific inhibitors of N-glycan processing. Pretreatment of human colon adenocarcinoma derived HT-29 cells with DMJ resulted in an expression of the 105 kD $\beta_1$ precursor chain and of smaller forms of the $\alpha_1$, $\alpha_3$, $\alpha_5$, and $\alpha_6$ integrin subunits in a time and dose dependent manner. HT-29 cells treated with DMJ adhered poorly to laminin (8% of untreated controls), collagen type IV (40%), and fibronectin (35%). Pretreatment of the cells with DNJ did not alter the molecular weight of the integrin chains expressed and reduced HT-29 adhesion to laminin and fibronectin only to 68% and 49% respectively. Adhesion to collagen type IV was increased to 124% by DNJ. These results show that N-glycan processing is essential for the function and expression of integrins in human colorectal cancer cells. An altered glycosylation of these adhesion receptors may contribute to a more invasive or metastatic phenotype in colorectal cancer.

Invasion and metastasis largely determine the clinical course of colorectal carcinomas. Despite multiple clinical trials survival from colorectal carcinomas after optimal surgical removal of the primary tumour has not significantly improved in the past 40 years. There is general agreement that a better understanding of the mechanisms of invasion and metastasis will lead to the development of new and more successful treatment strategies. During infiltrative growth and metastasis the transformed epithelial cells have to penetrate the basement membrane of the organ and metastasising tumour cells have to traverse vascular basement membranes on the way to tissue invasion from the circulation. The initial step of this migration through basement membranes is thought to be the adhesion of tumour cells, which is mainly mediated through binding of extracellular matrix components to tumour cell surface receptors. In this context the family of integrins is of interest. Integrins are non-covalently associated dimers of one $\alpha$ and one $\beta$ subunit. As originally described, integrins were divided into three sub-families, each with a common $\beta$ subunit capable of associating with a specific group of $\alpha$ subunits. More recent work has shown that there are at least 13 different $\alpha$ subunits and eight $\beta$ subunits, and that certain $\alpha$ subunits can combine with more than one $\beta$ subunit (for reviews see 8). The classical receptors for extracellular matrix components are found in the $\beta_1$ subfamily (synonymous with the very late activation antigens (VLA)). The $\beta_1$ subfamily comprises at least eight related complexes, each consisting of a $\beta_1$ chain with a distinct $\alpha$ chain companion. Members of the $\beta_1$ subfamily include receptors for fibronectin (VLA-3, VLA-4, VLA-5, and the $\alpha_6\beta_1$ complex), laminin (VLA-1, VLA-2, VLA-3, VLA-6, and VLA-7) and collagen types I and IV (VLA-1, VLA-2, and VLA-3). Most of these receptors are promiscuous in their ligand recognition, but VLA-5 and VLA-6 seem to be specific for fibronectin and laminin respectively.

It was previously shown that during the process of malignant transformation in the large intestine the expression of integrins was changed in a typical pattern. Compared with normal colonic epithelial cells, the expression of the $\alpha_3$ and $\alpha_5$ chains was already greatly reduced in adenomas, and completely lost in most colon carcinomas. By contrast, the $\alpha_6$, $\beta_1$ and $\beta_4$ expression was maintained in adenomas, whereas the transformation from benign to malignant neoplasms associated with infiltrative growth was characterised by diminished expression of $\alpha_6$ and $\beta_4$ chains.

An altered expression of such adhesion molecules may influence the aggressiveness of local infiltrative growth and metastasis in human cancers. As well as a changed pattern of integrins in carcinomas, differences in their functional state may cause pathological cell matrix interactions. In this context it is noteworthy that if maturation of glycans on VLA-5 was blocked, the receptor subunits remained non-functional despite apparently correct assembly and insertion into the plasma membrane. Because
the pattern of glycosylation of cell surface components is altered in colorectal cancer, we have analysed expression of integrins in cell membranes of colorectal carcinomas and the adjacent normal colonic mucosa with regard to the state of glycosylation. Also, the role of N-linked oligosaccharide processing on the cell surface expression and the function of \( \beta_1 \) integrins in human colon adenocarcinoma derived HT-29 cells were studied.

**Materials and methods**

**REAGENTS**

Fibronectin, isolated from human plasma, was obtained from Boehringer Mannheim (Mannheim, Germany). Murine Engelbreth-Holm-Swarm tumour derived laminin and type IV collagen were purchased from Collaborative Research Inc (Bedford, MA, USA). Cell culture reagents were purchased from Gibco BRL (Berlin, Germany). The glycosylation inhibitors desoxymannojirimycin and other reagents, if not otherwise mentioned, were obtained from Sigma (Deisenhofen, Germany). Carrier free Na\(^{22} \)I was from Amersham (Buckinghamshire, UK). Protein-A-Sepharose was purchased from Pharmacia (Uppsala, Sweden).

**ANTIBODIES**

The monoclonal antibodies against integrin chains used were anti-\( \alpha_1 \) mAB TS2/7\(^{10} \) (T-Cell-Science), anti-\( \alpha_2 \) mAB G19\(^{10} \) (Immunotech, Luminy, France), anti-\( \alpha_3 \) mAB VM2\(^{10} \) (gift of VB Morhenn, Menlo Park, CA), anti-\( \alpha_4 \) mAB P4G9,\(^{10} \) anti-\( \alpha_5 \) mAB P1D6,\(^{9} \) and anti-\( \alpha_6 \) mAB AMP77\(^{10} \) (Telios Inc, San Diego, CA), anti-\( \beta_1 \) mAB GOH3\(^{10} \) (donated by A Sonnenberg, Amsterdam, The Netherlands), anti-\( \beta_1 \) mAB 4B4\(^{10} \) (Coulter Clone, Krefeld, Germany), anti-\( \beta_2 \) mAB MHM23\(^{10} \) (Dako, Hamburg, Germany), anti-\( \beta_3 \) mAB SZ.21\(^{10} \) (Immunotech SA, Luminy, France), and anti-\( \beta_4 \) mAB J3\(^{10} \) (Telios Inc, San Diego, CA).

FITC-conjugated goat antimouse TgG or goat antirat TgG antibodies were purchased from Dako (Hamburg, Germany). Alkaline-phosphatase-conjugated antiserum or antirat IgG antibodies were from Sigma (Deisenhofen, Germany).

**TISSUES**

Intestinal tissues were obtained from eight patients (five men and three women, age range 52 to 82 years) with colorectal adenocarcinomas. In all cases, macroscopically and histologically normal adjacent mucosa (10 cm from the primary tumour) as well as tumour tissues were examined. Surgical resection specimens were obtained from the Department of Surgery at the Steglitz Medical Center immediately after their removal. After extensive washing in phosphate buffered saline (PBS; pH 7.2), normal mucosa scrapings and tumour tissues were frozen in liquid nitrogen and stored at \(-80^\circ \)C until use.

**ISOLATION OF CELL MEMBRANES**

Cell membranes of human colorectal carcinomas and normal mucosa were prepared as described by Maeda et al\(^{16} \) with minor modifications. Briefly, tumours or mucosal scrapings were homogenised in TEA buffer (250 mM sucrose, 10 mM triethanolamine (pH 7-6) containing 1 mM phenylmethylsulphonylfuoride (PMSF) and 1 mM N-ethylmaleimide as protease inhibitors) on ice and centrifuged at 1000 \( g \) for 10 minutes. The supernatant liquid was centrifuged for 20 minutes at 19,500 \( \times \) g. The fluffy white upper layer of the double pellet was resuspended in 15 ml of TEA buffer and loaded on 10 ml 41% sucrose. After centrifugation for 60 minutes at 96,000 \( g \), cell membranes were collected as a white interfacial band and pelleted by centrifugation at 48,000 \( g \) for 30 minutes. The pellet was analysed for ouabain sensitive Na/K-ATPase as a marker for basolateral cell membranes according to Evans.\(^{17} \)

**CHARACTERISATION OF INTEGRINS BY IMMUNOBBLOTTING**

Equal amounts of cell membrane protein from normal and carcinoma tissue were boiled for five minutes in SDS sample buffer and analysed by SDS-polyacrylamide gel electrophoresis according to Laemmli\(^{12} \) with 7% resolving gels. To identify \( \beta_1 \) integrins, resolved cell membrane proteins were transferred to nitrocellulose as described by Towbin et al.\(^{19} \) Nitrocellulose strips were blocked with blocking buffer (PBS containing 0-1% sodium azide, 0-3% TWEEN, and 2% powdered non-fat milk) at 4°C overnight and incubated with monoclonal antibodies against the integrin \( \beta_1 \) chain diluted 1:100 in blocking buffer for 60 minutes at room temperature. At the end of the incubation period, strips were washed three times for 30 minutes with blocking buffer. Bound antibodies were detected with antimouse-IgG antibodies coupled to alkaline phosphatase by the APAAP technique.

**CELL CULTURES**

The human colonic adenocarcinoma cell line HT-29 was obtained from the American Type Culture Collection (ATCC, USA). HT-29 cells were routinely cultured in Dulbecco’s modified Eagle’s medium (4.5 g/l glucose) supplemented with 10% heat inactivated fetal calf serum in 8% CO\(_2\) in air at 36-37°C. Media routinely changed three times a week.

Inhibitors of glucosidase I (deoxynojirimycin (DNJ)) and mannosidase I (1-deoxymannojirimycin (DMJ)) were used at optimum concentrations, as specified for HT-29 cells.\(^{30} \) Stock solutions of inhibitors were made and serially diluted in the culture media. Cells were pre-incubated in the presence of inhibitors of different concentrations for four to 48 hours before radiolabelling, cytofluorometry, or cell adhesion experiments, depending on the nature of the experiment as described in the text and figure legends. No significant loss of cell viability resulted from pretreatment as judged by trypan blue exclusion tests.
CELL-SURFACE LABELLING
Cell surface proteins were iodinated by the lactoperoxidase method as described by Hynes and Wyke. Briefly, confluent cell layers in 25 cm² culture bottles were washed twice with Ca²⁺/Mg²⁺ free PBS. Cells were harvested by incubation with 1 mM EDTA in tris buffered saline for 20 minutes and centrifuged at 1000 rpm for 10 minutes. A pellet of 10⁷ cells was resuspended in 360 μl HEPES-buffered saline (HBS) containing 150 μg lactoperoxidase and 1 mCi of carrier free Na¹²⁵I. The iodination reaction was initiated by adding 19 μl 0.1% H₂O₂. After incubation on ice for five minutes with intermittent swirling, another 19 μl aliquot of 0.1% H₂O₂ was added, and the reaction was continued for another 10 minutes. Unbound Na¹²⁵I was removed by washing the cells three times with HBS. Labelled cells were extracted in 500 μl of 200 mM O-octyl-β-D-glucopyranoside in HBS containing 1 mM PMSF with swirling of 20 minutes at 4°C. Extracts were clarified by centrifugation.

IMMUNOPRECIPITATION
Immunoprecipitation with mAbs was carried out as described by Sonnenberg et al with the modification: cell extracts were first incubated overnight at 4°C with 10 μl of the specific antibody and 10 μl of a species specific polyclonal rabbit IgG (Dako, Hamburg, Germany) antibody and then for an incubation period of one hour with 9 mg protein A sepharose at 4°C. After centrifugation at 5000 rpm for 10 minutes, the pelleted sepharose was washed twice with 10 mM Tris/HCl (pH 8.0), 0.5% sodium deoxycholate, 1% nonidet P40, and 0.1% SDS. The absorbed protein was eluted by boiling the pellet for five minutes in double concentrated SDS sample buffer with or without dithiothreitol as reducing agent. After polyacrylamide gel electrophoresis (see earlier) with 7% resolving gels, radioactive peptides were visualised after drying the gel at 60°C by exposure to Kodak X-Omat film at ~80°C for three to five days depending on the experiment.

QUANTIFICATION OF INTEGRINS BY FLOW CYTOMETRY
Flow cytometric analysis of expression of integrins on inhibitor treated and untreated HT-29 cells was conducted essentially as described. Briefly, after trypsinisation, HT-29 cells (2 x 10⁶) were incubated with monoclonal antibodies against different integrin subunits (see earlier) diluted 1:5 to 1:50 with FACS buffer (PBS containing 10% FCS and 0.1% sodium azide) in a total volume of 50 μl for one hour at 4°C. After two washes with 1 ml FACS buffer, cells were incubated with FITC conjugated goat antimouse IgG or goat antirat IgG antibodies diluted 1:10 for one hour at 4°C, followed by another two washes. Non-specific staining was assessed by omission of the primary antibody. Cells were then analysed on a FACSCAN (Becton Dickinson) flow cytometer.

ADHESION ASSAYS
Cell adhesion assays were described recently in detail. Briefly, microwells were coated with intact mouse laminin, type IV collagen, human serum fibronectin, or bovine serum albumin (BSA) for 90 minutes at 36°C and washed once with PBS. HT-29 cells were washed with PBS and harvested by a 10 minute incubation with 0.05% trypsin/0.02% EDTA 24 hours after reaching confluency. The reaction was stopped by addition of 10% fetal calf serum in DMEM, cells were pelleted by centrifugation (300 g/10 min) and resuspended in serum free medium. Cells (50 000) in serum free medium were added to each coated well and incubated for various times at 36°C. At the end of the incubation period, plates were gently washed twice with 100 μl of PBS to remove unattached cells. After staining, dishes were photographed (Yashica, Ilford HP5 films), and adherent cells were counted from the photographs. To test the

Integrated expression in HT-29 cells

<table>
<thead>
<tr>
<th>Monoclonal antibody</th>
<th>Positive cells</th>
<th>Intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>α₁</td>
<td>60 ± 3 (31-0)</td>
<td>10 ± 1 (5-2)</td>
</tr>
<tr>
<td>α₂</td>
<td>98 ± 1 (1-1)</td>
<td>44 ± 1 (5-4)</td>
</tr>
<tr>
<td>α₃</td>
<td>97 ± 7 (1-9)</td>
<td>38 ± 3 (15-1)</td>
</tr>
<tr>
<td>α₄</td>
<td>2 ± 1 (0-1)</td>
<td>3 ± 1 (2-1)</td>
</tr>
<tr>
<td>α₅</td>
<td>4 ± 1 (1-4)</td>
<td>3 ± 1 (1-1)</td>
</tr>
<tr>
<td>α₆</td>
<td>9 ± 1 (0-4)</td>
<td>19 ± 1 (3-1)</td>
</tr>
<tr>
<td>α₇</td>
<td>98 ± 1 (0-4)</td>
<td>39 ± 1 (6-6)</td>
</tr>
<tr>
<td>β₁</td>
<td>95 ± 1 (5-1)</td>
<td>39 ± 1 (20-6)</td>
</tr>
<tr>
<td>Indifferent IgG</td>
<td>2 ± 1 (0-7)</td>
<td>2 ± 1 (1-2)</td>
</tr>
</tbody>
</table>

Composite of integrin subunit expression on HT-29 cells. Integrin expression was analysed by flow cytometry with specific primary antiintegrin antibodies and fluorescent second antibody. Values are mean (SD) of three independent experiments.
inhibition of HT-29 cell adhesion to these extracellular matrix components, cells were pre-incubated with varying concentrations of monoclonal antibodies against integrin subunits for one hour at 4°C before seeding on coated microwells.

STATISTICAL ANALYSIS
Statistical significance was determined by the Wilcoxon rank test at p<0.05.

Results

EXPRESSION OF β1 INTEGRINS IN CELL MEMBRANES OF COLORECTAL CARCINOMAS AND NORMAL COLONIC MUCOSA
Expression of β1 integrins by normal colonic epithelial cells and malignant epithelial cells from colorectal carcinomas was examined with the immunoblot technique. With a β1 chain specific antibody, expression of a characteristic β1 chain (130 kD under reducing and 116 kD under non-reducing conditions) could be shown in isolated basolateral cell membranes of normal colonic mucosa. By contrast, in cell membranes of colorectal carcinomas, two bands representing the mature β1 and the β1 precursor form (105 kD under non-reducing conditions) were detected in five of eight carcinomas (Fig 1). In three carcinomas a broad β chain (100–115 kD) was stained, indicating that a putative pre β and β chain were not completely separated under these experimental conditions.

EXPRESSION OF INTEGRINS ON HT-29 CELLS
In an attempt to further identify cell adhesion receptors, flow cytometry was performed with antibodies against various α and β subunits of integrins. Flow cytometric analysis showed that HT-29 cells expressed α1, α2, α3, α6, αv, β1, and β2 chains of integrin cell adhesion receptors. No positive cell staining was seen with monoclonal antibodies against the α4, α5, α7, and β3 chains. The specificity of the antibodies was further confirmed by immunoprecipitation of integrin chains from cell lysates after 125I-lactoperoxidase cell surface labelling with the indicated antibodies. In accordance with flow cytometry, we identified the α1, α2, α3, α6, αv, β1 and β2 integrin subunits in HT-29 cell membranes. Also, no α4, α5, β2, and β3 chains of integrins were detected (data not shown).

EFFECT OF DNJ AND DMJ ON THE CELL SURFACE EXPRESSION OF β1 INTEGRINS ON HT-29 CELLS
The amount of integrins expressed on the surface of inhibitor treated and untreated cells was analysed by indirect immunofluorescent staining with monoclonal antibodies against integrin subunits followed by flow cytometric analysis on a FACSCAN (Becton-Dickinson) flow cytometer. This analysis showed that HT-29 cells express the α1, α2, α3, α6, and β1 chain of the integrin cell adhesion receptor family. Also, significant expression of the αv chain was found (see Table). No positive cell staining was seen if monoclonal antibodies against the α4, the α5, the β2, and the β3 chains were used. Figure 2 shows that treatment of HT-29 cells with DNJ and DMJ for 48 hours reduced the expression of α3, αv, and β1 to 55% to 70% of that of untreated controls. Reduction of α3 staining was less intense (70%–80%) and staining intensity of the α1 chain was not significantly altered. The staining intensity of all these integrin chains was similar in DNJ and DMJ treated HT-29 cells. By contrast, the expression of the αv containing fibronectin binding integrin was reduced to 53% by treatment with DNJ but was not altered by DMJ.

STRUCTURE OF β1 INTEGRINS ON HT-29 CELLS TREATED WITH DMJ OR DNJ
The effect of N-linked oligosaccharide trimming and processing on the molecular weight of β1 integrins on HT-29 cells was investigated with specific inhibitors of glucosidase I (DNJ) and mannosidase I (DMJ). Equivalent numbers of HT-29 cells were incubated for 48 hours with 3 mM DNJ or DMJ or left untreated. Cell surface molecules were then labelled with 125I, and the αβ heterodimers containing β1 were immunoprecipitated with mAb 4B4 and resolved by SDS-PAGE. As described previously, β1 integrins on the cell surface of untreated cells migrate under non-reducing conditions as three major bands: a strong signal averaging at 115 kD representing the mature β1 subunit, a broad signal between 140–160 kD at positions of the α2, α5, and αv chains, and a weak signal at 200 kD of the α1 chain (Fig 3). Inhibition of the mannosidase I for 48 hours by DMJ results in the cell surface expression of the minor pre-β1 chain of about 105 kD and a minor α1 chain of about 190 kD. As well as the α chain band at 140–160 kD a further signal was seen at 130 kD. Immunoprecipitation experiments with monoclonal antibodies against α subunits showed that this pre-α band mainly contains the smaller forms of α3 and
\( \alpha \) chains, whereas the molecular weight of the \( \alpha_2 \) chain is not altered by DMJ treatment (data not shown). After inhibition of the glucosidase I by DNJ no change in the molecular weight of the integrin subunits was found.

**Kinetcs of Turnover of \( \beta_1 \)-Integrins on HT-29 Cells in the Presence of DMJ**

HT-29 cells were incubated with the mannosidase I inhibitor DMJ for various times and \( \beta_1 \) integrins were immunoprecipitated from 125I-surface labelled cells and analysed by SDS-PAGE followed by autoradiography. After four hours of incubation with DMJ, no pre-\( \beta \) chains were found and after a 12 hour incubation period, most of the \( \beta_1 \) integrin complexes on the cell surface still contained the mature \( \beta_1 \) chain but some the smaller pre-\( \beta \) chain (Fig 4). After a 24 hour incubation with DMJ, 50% of \( \beta_1 \) integrins were replaced by pre-\( \beta_1 \) containing integrins. After a 48 hour incubation period, most \( \beta_1 \) integrins contained the pre-\( \beta \) chain. These data indicate a half life of \( \beta_1 \) integrins on HT-29 cells of about 20–24 hours under these experimental conditions, but we cannot rule out the probability that in the presence of DMJ the turnover rate of these adhesion receptors differs from that of untreated cells.

**Adhesion of HT-29 Cells to Various Extracellular Matrix Components**

We first investigated the adhesion of HT-29 cells to various extracellular matrix components. Figure 5 shows that the time course of HT-29 cell adhesion to these substrates was remarkably different. After six hours of incubation, HT-29 cells showed maximal adhesion to type IV collagen. An increase in the incubation time did not change plating efficiencies (data not shown) and plateau values for adhesion to type IV collagen varied between 80% and 85% of total cells seeded. With this rate of adhesion set as 100%, only 2.5 (1%) (mean 1 SD) of the cells adhered to BSA in serum free medium after six hours. Within 30 minutes, only 0.5 (0.2)% of cells adhered to BSA to 81 (9)% to type IV collagen. A significant adhesion after six hours was also found for laminin (76 (10%)) and fibronectin (66 (7%) (p<0.001) (Fig 2). Under all experimental conditions, HT-29 cells showed a greater adhesion to type IV collagen than to laminin or fibronectin.

**Integrin Mediated Cell Adhesion of HT-29 Cells**

To define more precisely the interaction between HT-29 cells and extracellular matrix components, we tested the effect of added antibodies against different integrin chains. Adhesion of HT-29 to laminin is mediated by the \( \alpha_6 \beta_1 \) integrin complex, as the monoclonal antibody 4B4 directed against the integrin \( \beta_1 \) chain and the monoclonal antibody GOH3 against the \( \alpha_6 \) chain abolished cell adhesion to laminin (Fig 6). Pre-treatment of HT-29 cells with monoclonal antibodies against \( \alpha_6 \) or \( \beta_1 \) significantly inhibited cell adhesion to type IV collagen, indicating that HT-29 adhesion to the basement membrane component type IV collagen as well as to laminin is mediated by \( \beta_1 \) containing integrins. With fibronectin substrates on the other hand, only the monoclonal antibody against the \( \alpha_6 \) chain was inhibitory. These results indicated that \( \alpha_6 \) containing integrins are essential for adhesion of these tumour cells to fibronectin.

**Effect of DNJ and DMJ on Cell Adhesion to Laminin, Type IV Collagen, and Fibronectin**

To examine the function of \( \beta_1 \) integrins on DMJ or DNJ treated HT-29 cells, we assayed the...
5: Time
adhesion
of HT-29 cells
in vitro
At the
substrate for 90
min, laminin,
type IV
collagen, and
fibronectin, and
bone
serum albumin (BSA) in
two
at 36°C. All
dishes were
coated with 5 µg/cm² of
substrate for 90 minutes
at 36°C. At the indicated
times, unattached cells
were
removed by washing and
adherent
cells were stained
with amido black and
counted. Values are the
means of three independent
experiments. In each
experiment 10 microwells
were coated with the
different substrates; (SD
<10% in all experiments;
*p<0.05 vs BSA;
**p<0.001 vs BSA).

Discussion
There is growing evidence that β1 integrin
mediated interactions between the extracellular
matrix and cancer cells can regulate the process
of infiltrative growth and metastasis. Our data
show that malignant transformed epithelial cells
of colorectal carcinomas expressed a 105 kD non-reduced
precursor form of the β1 chain not found in epithelial
cells of the normal mucosa. The differences in electrophoretic mobility between the pre-β1 and mature β1 chain were
probably due to structural differences in the glycans
portion, as it was abolished after enzymatic deglycosylation of the receptors in

normal epithelial cell membranes (data not shown). Differences in the glycosylation of cell
surface components of colorectal cancer cells have been previously shown.5 That the
detection of pre-β1 chains in isolated cell membranes of colorectal carcinomas with the immunoblot technique reflects contaminations from an intra-
acellular pool of pre-β1 polypeptides cannot, however, be excluded. Akiyama et al showed that in
transformed cells the turnover of β1 integrins is increased, leading to a decrease in the intracellular pool of pre-β1 polypeptides compared with
normal cells.1 Contamination of isolated cell membranes with intracellular components
would therefore probably result in the detection of pre-β1 chains in the normal colonic mucosa.

To further characterise the relevance of N-linked oligosaccharides for β1 integrin
receptor expression and function in malignant
colonic epithelial cells, cell culture experiments
were performed with HT-29 cells, cell line
derived from a human adenocarcinoma. In a first
attempt to characterise β1 integrin cell
membrane expression, flow cytometry analysis was
performed with antibodies against various α
chains of the β1 family of integrins after pre-
treatment with DMJ or DNJ. We found that
depression of various α subunits was modified by
DNJ or DMJ treatment in different patterns.

Pretreatment with DMJ and DNJ, for example,
reduced expression of the α5 and β1 chains to
60%–70% of untreated control values, whereas
expression of the α1 chain remained unchanged.
Expression of the α1 chain not altered by DMJ treatment
but was reduced to 53% by DNJ. A diminished
receptor expression may be due to reduced
membrane insertion or increased degradation of
the receptor in inhibitor treated cells. In
agreement with our results, Spiro et al recently
reported that inhibition of the glucosidase I by
DNJ delayed maturation and membrane
insertion of the α5β1 vitronectin receptor in
human melanoma cells and resulted in a 50%
reduced cell surface expression, whereas pre-
treatment with DMJ did not alter the vitronectin receptor expression. Immunoprecipitation experiments from $^{125}$I labelled cells were performed to further characterise the molecular mechanisms by which inhibitors of glycosylation modify $\beta_1$ integrin receptor expression. We have shown that pretreatment with DNJ had no apparent effect on the molecular weight of $\beta_1$ integrins in HT-29 cells. By contrast, inhibition of mannosidase I with DMJ reduced the molecular weight of several $\alpha$ chains and led to the expression of the smaller 105 kD pre-$\beta_1$ chain on the cell surface. Similar results were reported for DMJ treatment of fibroblasts, which blocked maturation of the pre-$\beta_1$ to the mature $\beta_1$ chain. Because the N-linked oligosaccharides synthesised in the presence of DNJ contain maximally four sugar residues more than those synthesised in the presence of DMJ, most of the 13 potential N-glycosylation sites on the $\beta_1$ protein have to be glycosylated to account for the difference in molecular weight between the $\alpha_1$ chains in DMJ and DNJ treated cells. The effect of DMJ was dose and time dependent, indicating a 20–24 hour half life of the $\beta_1$ chain in HT-29 cells under these experimental conditions.

Besides an altered expression of integrin adhesion molecules in colorectal cancer, an altered function may also result in pathological cell matrix interactions. Evidence has been found for the involvement of integrin glycosylation in the modulation of cell matrix interaction. Reduction in erythroleukaemia cell adhesion after phorbol ester treatment caused by reduced glycosylation of $\alpha_\beta_1$ was recently reported. To further characterise the relevance of glycosylation of integrins for their function as cell adhesion receptors we performed initial experiments to analyse the integrin mediated cell matrix interaction in HT-29 cells, and were able to show that inhibition of golgi mannosidase I by DMJ resulted in a significantly decreased adhesion of DMJ treated HT-29 cells to laminin, type IV collagen, and fibronectin. Also inhibition of the glucosidase I by DNJ significantly reduced HT-29 adhesion to laminin and fibronectin although less effectively than DMJ treatment. Attachment of HT-29 cells to type IV collagen was increased by treatment with DMJ.

The reduced adhesion of DMJ treated HT-29 cells towards the extracellular matrix components tested cannot be simply explained by a diminished expression of integrin receptors, because the effect of DNJ on the expression of integrins was similar or greater than that of DMJ, but inhibition of cell adhesion was less efficient. This suggests that the presence of N-linked oligosaccharides is required for the function of the integrin receptors. This conclusion is further corroborated by the finding that DNJ increases the adhesion of HT-29 cells to type IV collagen despite unchanged or diminished expression of $\alpha_1$ and $\beta_1$ chains mediating this binding. A similar effect of DNJ on integrin mediated cell adhesion to collagens has been described for several myoblast cell lines. The role of glycans on integrin receptors differs from that on some other higher affinity receptors examined. For example, the insulin or epidermal growth factor receptors retain surface expression if oligosaccharides are present but incompletely processed. In the case of the insulin receptor, the deglycosylated receptor retains its ability to bind to insulin.

Studies on the role of glycosylation in malignancy are complicated by identification of the relevant target molecule. Recent studies have shown that inhibitors of the N-glycan processing reduce metastatic growth of tumour cells of different histological types and origins. A change in a single enzyme will generally influence a multitude of substrate proteins and lipids. It is not easy to find out which substrate molecule is implicated in a particular phenotypic or functional change, if any. Thus it seems clear that malignant transformation can affect the expression, distribution, and function of glycosylated cell surface components such as integrins, but the pattern of changes may be complex. Our data may, however, serve as a basis for further studies aiming at the identification of regulatory factors (for example, hormones, lymphokines, cytokines) that modulate the expression and function of integrins of colorectal cancer cells. This might open up new concepts for influencing local tumour growth and metastasis of colonic malignancies.

We thank Dr A Sonnenberg and Dr V Morhenn for providing antibodies. This work was supported by Grants Ri 1962/1-3 of the Deutsche Forschungsgemeinschaft, and a pregraduate grant of the Free University of Berlin (to B.V.). We gratefully acknowledge the expert technical assistance of Petra Weinginger.

9 Sonnenberg A, Linders CTT, Modderman PW, Damsky CH, Aumailly M, Timpl R. Integrin recognition of different cell-binding fragments of laminin (P1, E3, E8) and evidence that $\alpha_6\beta_1$ but not $\alpha_5\beta_1$ functions as a major receptor for fragment E8. J Cell Biol 1990; 110: 2143–55.
Altered glycosylation of integrin adhesion molecules in colorectal cancer cells and decreased adhesion to the extracellular matrix.

B von Lampe, A Stallmach and E O Riecken

Gut 1993 34: 829-836
doi: 10.1136/gut.34.6.829

Updated information and services can be found at:
http://gut.bmj.com/content/34/6/829

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Colon cancer (1547)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/